168 CHAPTER 8 17. Khan F, Huang H, Datta YH. Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation. J Thromb Thrombolysis. 2016;42(4):573–8. 18. Kim HM, Choi EK, Park CS, Cha MJ, Lee SY, Kwon JM, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation. PLoS One. 2019;14(3):e0211766. 19. Kwon CH, Kim M, Kim J, Nam GB, Choi KJ, Kim YH. Real-world comparison of nonvitamin K antagonist oral anticoagulants and warfarin in Asian octogenarian patients with atrial fibrillation. J Geriatr Cardiol. 2016;13(7):566–72. 20. Lafon T, Vallejo C, Hadj M, Laroche ML, Geniaux H. Misuse and adverse effects of new direct oral anticoagulants: a prospective observational study in patients admitted to an emergency unit of a French university hospital. Therapie. 2017;73(3):209–15. 21. Mitrovic D, Drost-Wijnne J, Jochemsen G, Meijerink H. Richtlijnadherentie bij het voorschrijven van direct werkende orale anticoagulantia. Nederlands Platform voor Farmaceutisch Onderzoek. 2017;2:a1640. 22. Nahornyj E, Goutelle S, Bourguignon L, Gastine B de la. Evaluation of direct oral anticoagulants (DOACs) prescriptions in geriatric hospital over 3 years. Therapies. 2021;76(3):191–200. 23. Paciaroni M, Agnelli G, Caso V, Silvestrelli G, Seiffge DJ, Engelter S, et al. Causes and risk factors of cerebral ischemic events in patients with atrial fibrillation treated with nonvitamin K antagonist oral anticoagulants for stroke prevention: the RENo study. Stroke. 2019;50(8):2168–74. 24. Rutherford OCW, Jonasson C, Ghanima W, Söderdahl F, Halvorsen S. Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation. Heart. 2022;108(5):345-52. 25. Shinoda N, Mori M, Tamura S, Korosue K, Kose S, Kohmura E. Risk of recurrent ischemic stroke with unintended low-dose oral anticoagulant therapy and optimal timing of review. J Stroke Cerebrovasc Dis. 2018;27(6):1546–51. 26. Shinohara M, Fujino T, Yao S, Yano K, Akitsu K, Koike H, et al. Assessment of the bleeding risk of anticoagulant treatment in non-severe frail octogenarians with atrial fibrillation. J Cardiol. 2019;73(1):7–13. 27. Shinohara M, Wada R, Yao S, Yano K, Akitsu K, Koike H, et al. Evaluation of oral anticoagulants in atrial fibrillation patients over 80 years of age with nonsevere frailty. J Arrhythm. 2019;35(6):795–803. 28. Szeto CLC, Hui KF. Residual stroke risk in patients with atrial fibrillation treated with nonvitamin K oral anticoagulants: an 8-year retrospective cohort study. Cerebrovasc Dis Extra. 2021;11(1):9–14. 29. Ting C, Rhoten M, Dempsey J, Nichols H, Fanikos J, Ruff CT. Evaluation of direct oral anticoagulant prescribing in patients with moderate to severe renal impairment. Clin Appl Thromb Hemost. 2021;27:1–8. 30. Tran E, Duckett A, Fisher S, Bohm N. Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment. J Thromb Thrombolysis. 2017;43(4):505–13. 31. Whitworth MM, Haase KK, Fike DS, Bharadwaj RM, Young RB, MacLaughlin EJ. Utilization and prescribing patterns of direct oral anticoagulants. Int J Gen Med. 2017;10:87–94. 32. Akagi Y, Chiba T, Uekusa S, Kato H, Yamamura S, Aoki Y, et al. Retrospective cohort study of the efficacy and safety of dabigatran: real-life dabigatran use including very low-dose 75 mg twice daily administration. J Pharm Health Care Sci. 2019;5:17. 33. Akao M, Chun YH, Esato M, Abe M, Tsuji H, Wada H, et al. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J. 2014;78(9):2166–72.
RkJQdWJsaXNoZXIy MTk4NDMw